State Street Corp Acquires 928 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

State Street Corp raised its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 0.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,530,464 shares of the company’s stock after purchasing an additional 928 shares during the quarter. State Street Corp owned 3.18% of Amphastar Pharmaceuticals worth $74,273,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in AMPH. Blue Trust Inc. lifted its holdings in shares of Amphastar Pharmaceuticals by 23.9% in the 2nd quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock valued at $70,000 after acquiring an additional 309 shares during the last quarter. Raymond James & Associates lifted its stake in shares of Amphastar Pharmaceuticals by 16.9% in the 2nd quarter. Raymond James & Associates now owns 114,719 shares of the company’s stock valued at $4,589,000 after purchasing an additional 16,574 shares during the last quarter. 1620 Investment Advisors Inc. purchased a new position in shares of Amphastar Pharmaceuticals in the 2nd quarter worth approximately $93,000. Louisiana State Employees Retirement System increased its position in shares of Amphastar Pharmaceuticals by 3.8% during the 2nd quarter. Louisiana State Employees Retirement System now owns 19,200 shares of the company’s stock valued at $768,000 after purchasing an additional 700 shares during the last quarter. Finally, AlphaCentric Advisors LLC bought a new stake in Amphastar Pharmaceuticals in the second quarter worth $1,000,000. 65.09% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP Rong Zhou sold 7,000 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $44.42, for a total value of $310,940.00. Following the completion of the sale, the executive vice president now owns 118,469 shares in the company, valued at approximately $5,262,392.98. The trade was a 5.58 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Richard K. Prins sold 10,000 shares of the firm’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $43.77, for a total value of $437,700.00. Following the transaction, the director now owns 30,471 shares in the company, valued at $1,333,715.67. The trade was a 24.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 41,533 shares of company stock valued at $1,987,482 in the last 90 days. Company insiders own 27.10% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on AMPH shares. Wells Fargo & Company assumed coverage on shares of Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They set an “equal weight” rating and a $55.00 price objective on the stock. StockNews.com downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $60.33.

Amphastar Pharmaceuticals Stock Performance

AMPH stock opened at $40.85 on Wednesday. Amphastar Pharmaceuticals, Inc. has a twelve month low of $36.56 and a twelve month high of $65.92. The firm has a market cap of $1.96 billion, a price-to-earnings ratio of 13.78, a PEG ratio of 0.87 and a beta of 0.78. The business’s fifty day simple moving average is $47.02 and its two-hundred day simple moving average is $44.64. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.